Filanesib
- Generic Name
- Filanesib
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22F2N4O2S
- CAS Number
- 885060-09-3
- Unique Ingredient Identifier
- 8A49OSO368
- Background
Filanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Phase 1
Completed
- Conditions
- Plasma Cell LeukemiaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 76
- Registration Number
- NCT01372540
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath